Drug Search Results
More Filters [+]


Alternative Names: diflorasone, psorcon, florone e, psorcon e, florone, apexicon e
Latest Update: 2024-07-09
Latest Update Note: Clinical Trial Update

Product Description

Diflorasone is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Diflorasone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching. (Sourced from: https://medlineplus.gov/druginfo/meds/a602019.html)

Mechanisms of Action: GR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Canada | Chile | Colombia | Germany | India | Ireland | Italy | Korea | Portugal | Spain | Taiwan | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diflorasone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events